MK-2866 and Rapamycin Interaction
MK-2866 and Rapamycin have an interaction requiring monitoring for interaction with 47% confidence. Both MK-2866 and Rapamycin negatively affect lipid profiles. Combined use may significantly worsen HDL/LDL ratios. Include lipid support and get bloodwork mid-cycle. These compounds primarily affect different organ systems.
Compound Profiles
MK-2866
Selective Androgen Receptor Modulator | Muscle Wasting Research
MK-2866 binds to the androgen receptor (AR) with high affinity and selectivity, functioning as a partial agonist in muscle and bone tissue. Upon binding, the MK-2866-AR complex undergoes a conformational change that promotes nuclear translocation and interaction with androgen response elements (AREs) on DNA, activating transcription of genes involved in protein synthesis, nitrogen retention, and myogenic differentiation.
View full profileRapamycin
mTOR Inhibitor | Longevity & Immunosuppression
Rapamycin exerts its effects by binding to the intracellular protein FKBP12, forming a complex that directly and specifically inhibits mechanistic target of rapamycin complex 1 (mTORC1). mTORC1 is a master nutrient-sensing kinase that integrates signals from growth factors, amino acids, energy status, and stress to regulate cell growth, proliferation, and metabolism.
View full profileCombined Organ Load
Shared Safety Flags
Frequently Asked Questions
Can I take MK-2866 with Rapamycin?
Yes, but with caution. Both MK-2866 and Rapamycin negatively affect lipid profiles. Combined use may significantly worsen HDL/LDL ratios. Include lipid support and get bloodwork mid-cycle. Regular monitoring is advised.
Is MK-2866 and Rapamycin safe together?
Based on pharmacological analysis, this combination is considered monitor. However, shared safety flags include: lipid disrupting. Monitor accordingly.
What are the interactions between MK-2866 and Rapamycin?
Both MK-2866 and Rapamycin negatively affect lipid profiles. Combined use may significantly worsen HDL/LDL ratios. Include lipid support and get bloodwork mid-cycle. This assessment has 47% confidence and is inferred from pharmacological mechanism analysis.
How should I time MK-2866 and Rapamycin?
MK-2866 has a half-life of ~24 hours and Rapamycin has a half-life of ~62 hours. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.
This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.